Announcement from
@novonordisk
re the FLOW trial:
Semaglutide reduced the risk of 50% decline in eGFR, kidney failure, or death due to kidney or cardiovascular disease by 24%
Results to be presented this year by trial PI
@VladoPerkovic
& colleagues
7
85
199
Replies
@brendonneuen
@novonordisk
@VladoPerkovic
The
#GilaMonster
is coming from deep within the
#AnimalHouse
to win this year's
#NephMadness
1
1
9
0
0
1
@brendonneuen
@jmteakell
@novonordisk
@VladoPerkovic
@jmteakell
apparently the universe grants my wish. Can't wait to see full results, especially since this was only 1.0mg dose. Another tool in the arsenal for CKD incoming!
1
0
2
@brendonneuen
@novonordisk
@VladoPerkovic
Great news. But the PR said nothing about weight loss which must have had an impact on BSA indexed eGFR. I guess we will find out when the FLOW trial is published.
2
2
29
@brendonneuen
@novonordisk
@VladoPerkovic
🎉
Let's see how much of the heavy lifting CVD mortality and weight-dependant CrCl formulas did
0
0
3
@brendonneuen
@novonordisk
@VladoPerkovic
Why are these trials so often presented by company name first?
We confuse drugs with companies e.g. “Pfizer vaccine” …giving them even more power to keep prices high and drugs out of reach of many…
0
0
0